Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2026-04-11 @ 8:10 AM
Study NCT ID:
NCT02318667
Status:
COMPLETED
Last Update Posted:
2021-01-27
First Post:
2014-12-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-02-27
Start Date Type:
ACTUAL
Primary Completion Date:
2017-06-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-09-05
Completion Date Type:
ACTUAL
First Submit Date:
2014-12-12
First Submit QC Date:
None
Study First Post Date:
2014-12-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-05-31
Results First Submit QC Date:
None
Results First Post Date:
2018-08-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-07
Last Update Post Date:
2021-01-27
Last Update Post Date Type:
ACTUAL